General Information of Drug (ID: DMORJD4)

Drug Name
AVB-500 Drug Info
Indication
Disease Entry ICD 11 Status REF
IgA nephropathy MF8Y Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMORJD4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Batiraxcept DM98NOU Ovarian cancer 2C73 Phase 3 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
AXL receptor tyrosine kinase ligand (GAS6) TT69QD2 GAS6_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04042623) Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Aravive.
3 Target-Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model-Informed Dose Selection for the First-in-Human Study of AVB-S6-500. Clin Transl Sci. 2020 Jan;13(1):204-211.